ACW pivotal Alzheimers trial database lock - results mid-Nov

• Xanamem Alzheimer's trial database locked
• Topline results expected mid-November
• Trial completed with 247 participants in Australia and the US

Actinogen Medical Ltd has announced that its pivotal XanaMIA phase 2b/3 Alzheimer's disease clinical trial has achieved database lock, confirming that topline results are expected in mid-November. The trial, which compares Xanamem 10 mg to placebo over 36 weeks, has completed all patient visits with 247 participants enrolled. Elevated pTau181 was used to select participants with a more progressive disease course, increasing the trial's power to detect a treatment effect. Positive results could establish brain cortisol control as an important part of Alzheimer's disease biology.